To further determine if the potent anti-tumor activity of T cells bearing a KIRS2/Dap12-CAR is dependent on the CD19 specificity, we generated an additional CAR targeting mesothelin (SS1 KIRS2/Dap12-BB). The gene discussed is CD19; the disease is neoplasm.